Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Sichuan Cancer Hospital and Research Institute
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04518852CT.gov TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC | — | Completed | — | — | — |
NCT01640665CT.gov Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors | — | Completed | — | — | — |
NCT01009593CT.gov Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Digestive System Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sorafenib (this asset) | Sichuan Cancer Hospital and Research Institute | P3 | BB · 67 |
| Capecitabine | China Medical University, China | P3 | BB |
| Irinotecan | Pfizer | P3 | BB |
| Fluorouracilum | Janssen Research & Development, LLC | P3 | B |
| pf-08634404 | Pfizer | P3 | B |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | Federico II University | P2 | B |
| Acetylcysteine | German Cancer Research Center | P2 | B |
| Linifanib | Abbott | P3 | B |
| Catequentinib | Zhejiang University | P2 | B |
+41 more in the Digestive System Neoplasm cohort
Other indications for Sorafenib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P4 | BBB · 79 |
| Portal Vein Thrombosis | — | P4 | BBB · 74 |
| Adult Hepatocellular Carcinoma | — | P3 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CapecitabineChina Medical University, ChinaBB
- IrinotecanPfizerBB
- FluorouracilumJanssen Research & Development, LLCB
- pf-08634404PfizerB
- L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))-Federico II UniversityB
Citation
Floatz Terminal. Sorafenib in Digestive System Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sorafenib-digestive-system-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →